Please note that this site is currently under development to reflect Celera's structural changes that were announced on January 9, 2006.

Celera Analyst & Investor Day
The Pierre Hotel
Thursday, June 22, 2006 | New York, NY
8:30-9:00 - Continental Breakfast & Registration
9:00-12:30 - Program

Click here for webcast

To reserve your place at this meeting, please contact David Speechly at 510-749-1853 or david.speechly@celera.com

Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.[ Read more ]

Celera's first FDA-cleared product is designed to detect mutations in the Human Immunodeficiency Virus (HIV-1) that are associated with drug resistance.   [ Learn more ]

June 15, 2006
Celera Genomics to Webcast Its Analyst and Investor Meeting on Thursday, June 22, 2006

May 11, 2006
Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks